source
- Intellia finds genetic marker linked to liver enzyme spikes in CRISPR ATTR amyloidosis trialIntellia Therapeutics announced that analysis of its ongoing CRISPR gene-editing trial for transthyretin (ATTR) amyloidosis has identified a common genetic variant among participants who experience…
- Braveheart Bio targets $382 million IPO to fund cardiac drug developmentBraveheart Bio announced an upsized initial public offering on the Nasdaq, aiming to raise about $382.5 million. The company will sell 21.2 million shares at $18 each under the ticker BRVE. The pr…